Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer
Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.
Related Articles
FDA Releases Draft Guidance on Tissue Biopsies in Clinical Trials
The FDA has issued a draft guidance offering recommendations regarding tissue biopsies in clinical trials for pediatric and adult patients.
Learn about cancer prevention and early detection
When it comes to cancer prevention and early detection, knowledge can be power.
Current Treatment Protocols for Ph+ ALL Treatment
Josep Maria Ribera, MD, PhD, discusses the current standard treatment protocols for Philadelphia chromosome-positive acute lymphoblastic leukemia and the rationale behind them.
Acalabrutinib Regimen Demonstrates Efficacy in De Novo Mantle Cell Lymphoma
An acalabrutinib triplet elicited a high response rate in patients with de novo mantle cell lymphoma.
Surveillance for Cutaneous Malignant Neoplasms Recommended in Post-BMT Patients – Oncology Nurse Advisor
Researchers explored the risks for basal cell carcinoma, squamous cell carcinoma, and melanoma in patients who underwent BMT.
Dr Shah on the Effects of IVIG on Teclistamab-Associated Infection Risk in Myeloma
Mansi R. Shah, MD, on the effects of IVIG on infections in recipients of teclistamab therapy for multiple myeloma.
FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer
Dostarlimab received breakthrough therapy designation from the FDA for locally advanced dMMR/MSI-H rectal cancer.
A Perspective on the MARS2 Trial
The phase 3 randomized controlled trial of extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (PM) (MARS2) reported “extended pleurectomy decortication was…
Bosutinib Yields Long-Term Efficacy and Safety in TKI-Pretreated CML
Treatment with bosutinib led to high response rates with a manageable safety profile in patients with CML who had previously received a TKI.